Usefulness of ^99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis

References

• Perfetto F, Cappelli F, Bergesio F, Ciuti G, Porciani MC, Padeletti L, Moggi Pignone A. Cardiac amyloidosis: the heart of the matter. Int Emerg Med 2013;8:191–203
   PubMed Web of Science ®Google Scholar
• Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528–40
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Halwani O, Delgado DH. Cardiac amyloidosis: an approach to diagnosis and management. Expert Rev Cardiovasc Ther 2010;8:1007–13
   PubMedGoogle Scholar
• Deux JF, Damy T, Rahmouni A, Mayer J, Plante-Bordeneuve V. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. Amyloid 2014;21:246–55
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imag 2011;38:470–8
   PubMed Web of Science ®Google Scholar
• Sachchithanantham S, Wechalekar AD. Imaging in systemic amyloidosis. Br Med Bull 2013;107:41–56
   PubMed Web of Science ®Google Scholar
• Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, Dierckx RA. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imag 2009;36:702–14
   PubMed Web of Science ®Google Scholar
• Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35–44
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Miller EJ. Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up? Circ Cardiovasc Imag 2013;6:162–4
   PubMed Web of Science ®Google Scholar
• Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271–83
   PubMed Web of Science ®Google Scholar
• Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 2013;20:212–20
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84
   PubMed Web of Science ®Google Scholar
• Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 1984;52:321–6
   PubMedGoogle Scholar
• Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612–15
   PubMed Web of Science ®Google Scholar
• Ak I, Vardareli E, Erdinc O, Kasapoglu E, Ata N. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med 2000;25:826–7
   PubMed Web of Science ®Google Scholar
• Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, Bauer R. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imag 2002;29:376–9
   PubMed Web of Science ®Google Scholar
• Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imag 2003;19:225–7
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc imag 2011;4:659–70
   PubMed Web of Science ®Google Scholar
• Lee VW, Caldarone AG, Falk RH, Rubinow A, Cohen AS. Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection. Radiology 1983;148:239–42
   PubMed Web of Science ®Google Scholar
• de Haro-del Moral FJ, Sanchez-Lajusticia A, Gomez-Bueno M, Garcia-Pavia P, Salas-Anton C, Segovia-Cubero J. Role of cardiac scintigraphy with (99)mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol 2012;65:440–6
   PubMed Web of Science ®Google Scholar
• Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imag 2014;15:1289–98
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imag 2013;6:195–201
   PubMed Web of Science ®Google Scholar
• Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imag 2014;7:502–10
   PubMed Web of Science ®Google Scholar
• Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Rocken C, Hardt S, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164:179–84
   PubMed Web of Science ®Google Scholar
• Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Translat Res 2015;8:117–27
   PubMed Web of Science ®Google Scholar